Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study

被引:104
|
作者
Falcone, Marco [1 ]
Tiseo, Giusy [1 ]
Giordano, Cesira [2 ]
Leonildi, Alessandro [1 ]
Menichini, Melissa [2 ]
Vecchione, Alessandra [2 ]
Pistello, Mauro [3 ,4 ]
Guarracino, Fabio [5 ]
Ghiadoni, Lorenzo [6 ]
Forfori, Francesco [7 ]
Barnini, Simona [2 ]
Menichetti, Francesco [1 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Infect Dis Unit, Pisa, Italy
[2] Azienda Osped Univ Pisana, Microbiol Unit, Pisa, Italy
[3] Univ Pisa, Virol Unit, Dept Lab Med, Pisa Univ Hosp, Pisa, Italy
[4] Univ Pisa, Retrovirus Ctr, Dept Translat Res, Pisa, Italy
[5] Azienda Osped Univ Pisana, Dept Anaesthesia & Crit Care Med, Pisa, Italy
[6] Univ Pisa, Dept Clin & Expt Med, Emergency Med Unit, Pisa, Italy
[7] Univ Pisa, Dept Surg Med & Mol Pathol & Crit Care Med, Pisa, Italy
关键词
D O I
10.1093/jac/dkaa530
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Bacterial and fungal superinfections may complicate the course of hospitalized patients with COVID-19. Objectives: To identify predictors of superinfections in COVID-19. Methods: Prospective, observational study including patients with COVID-19 consecutively admitted to the University Hospital of Pisa, Italy, between 4 March and 30 April 2020. Clinical data and outcomes were registered. Superinfection was defined as a bacterial or fungal infection that occurred >= 48 h after hospital admission. A multivariate analysis was performed to identify factors independently associated with superinfections. Results: Overall, 315 patients with COVID-19 were hospitalized and 109 episodes of superinfections were documented in 69 (21.9%) patients. The median time from admission to superinfection was 19 days (range 11-29.75). Superinfections were caused by Enterobacterales (44.9%), non-fermenting Gram-negative bacilli (15.6%), Gram-positive bacteria (15.6%) and fungi (5.5%). Polymicrobial infections accounted for 18.3%. Predictors of superinfections were: intestinal colonization by carbapenem-resistant Enterobacterales (OR 16.03, 95% CI 6.5-39.5, P< 0.001); invasive mechanical ventilation (OR 5.6, 95% CI 2.4-13.1, P< 0.001); immunomodulatory agents (tocilizumab/baricitinib) (OR 5.09, 95% CI 2.2-11.8, P< 0.001); C-reactive protein on admission >7 mg/dl (OR 3.59, 95% CI 1.7-7.7, P= 0.001); and previous treatment with piperacillin/tazobactam (OR 2.85, 95% CI 1.1-7.2, P= 0.028). Length of hospital stay was Longer in patients who developed superinfections ompared with those who did not (30 versus 11 days, P< 0.001), while mortality rates were similar (18.8% versus 23.2%, P= 0.445). Conclusions: The risk of bacterial and fungal superinfections in COVID-19 is consistent. Patients who need empiric broad-spectrum antibiotics and immunomodulant drugs should be carefully selected. Infection control rules must be reinforced.
引用
收藏
页码:1078 / 1084
页数:7
相关论文
共 50 条
  • [1] PREDICTORS AND OUTCOMES OF BACTERIAL AND FUNGAL SUPERINFECTIONS IN CRITICALLY ILL PATIENTS WITH COVID-19
    Yaqoob, Hamid
    Rizwan, Muhammad
    Greenberg, Daniel
    Arshad, Aleena
    Epelbaum, Oleg
    Chandy, Dipak
    CHEST, 2021, 160 (04) : 591A - 591A
  • [2] Bacterial and fungal superinfections in critically ill patients with COVID-19
    Bassetti, Matteo
    Kollef, Marin H.
    Timsit, Jean-Francois
    INTENSIVE CARE MEDICINE, 2020, 46 (11) : 2071 - 2074
  • [3] Predictors and outcomes of respiratory bacterial coinfections in patients with COVID-19 admitted to hospital: An observational prospective study
    Tiseo, Giusy
    Suardi, Lorenzo Roberto
    Giusti, Lisa
    Forniti, Arianna
    Caroselli, Claudio
    Galfo, Valentina
    Occhineri, Sara
    Leonildi, Alessandro
    Moscato, Giovanna
    Menichetti, Francesco
    Falcone, Marco
    RESPIROLOGY, 2022, 27 (11) : 987 - 990
  • [4] Bacterial and fungal superinfections in critically ill patients with COVID-19
    Matteo Bassetti
    Marin H. Kollef
    Jean-Francois Timsit
    Intensive Care Medicine, 2020, 46 : 2071 - 2074
  • [6] The Simple Predictors of Pseudomembranous Colitis in Patients with Hospital-Acquired Diarrhea: A Prospective Observational Study
    Yang, Bo Kyung
    Do, Byung Ju
    Kim, Eun Jung
    Lee, Ji Un
    Kim, Mi Hee
    Kang, Jin Gu
    Kim, Hyoung Su
    Kim, Kyung Ho
    Jang, Myoung Kuk
    Lee, Jin Heon
    Kim, Hak Yang
    Shin, Woon Geon
    GUT AND LIVER, 2014, 8 (01) : 41 - 48
  • [7] A comparison of characteristics and outcomes of patients with community-acquired and hospital-acquired COVID-19 in the United Kingdom: An observational study
    Shiwani, Haaris A.
    Bilal, Muhammad
    Shahzad, Muhammad U.
    Rodrigues, Alson
    Suliman, Jehad A.
    Soban, Muhammad
    Mirza, Shahzeb
    Lotca, Nicoleta
    Ruslan, Mohammed R.
    Memon, Danyal
    Arshad, Muhammad A.
    Fatima, Kiran
    Kamran, Asma
    Egom, Emmanuel E.
    Aziz, Abdul
    RESPIRATORY MEDICINE, 2021, 178
  • [8] COVID-19 and improved prevention of hospital-acquired infection
    Hu, Ling-Qun
    Wang, Jin
    Huang, Anna
    Wang, Danzhao
    Wang, Jingping
    BRITISH JOURNAL OF ANAESTHESIA, 2020, 125 (03) : E318 - E319
  • [9] Hospital-acquired bacterial infections in coronavirus disease 2019 (COVID-19) patients in Israel
    Schwaber, Mitchell J.
    Temkin, Elizabeth
    Lobl, Rona
    Schechner, Vered
    Nutman, Amir
    Carmeli, Yehuda
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2023, 44 (09): : 1437 - 1442
  • [10] Impact of the COVID-19 pandemic on multidrug-resistant hospital-acquired bacterial infections
    Bongiovanni, M.
    Barilaro, G.
    Zanini, U.
    Giuliani, G.
    JOURNAL OF HOSPITAL INFECTION, 2022, 123 : 191 - 192